Journal of Rheumatic Diseases

Table. 4.

Cumulative incidence of non-serious adverse events and serious adverse events

Adverse events Cumulative incidence (%)
Non-serious adverse events
Rash 2.27
Injection site erythema 2.27
Injection site pruritus 2.27
Injection site rash 1.14
Increased antinuclear antibody 1.14
Increased CRP 1.14
Diabetes mellitus 1.14
Increased RBC sedimentation rate 1.14
Decreased hemoglobin 1.14
Rosacea 1.14
Serious adverse events
Deep vein thrombosis 1.14
Diabetes mellitus 1.14
Intervertebral disc protrusion 1.14
Pneumonia bacterial 1.14
Spinal column stenosis 1.14

CRP: C-reactive protein, RBC: red blood cell.

J Rheum Dis 2021;28:68~75 https://doi.org/10.4078/jrd.2021.28.2.68
© J Rheum Dis